ArticleMolecular cancer2018
Transcriptome reprogramming by cancer exosomes: identification of novel molecular targets in matrix and immune modulation.
Article in Molecular cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 1 synthesis or guideline pooled it, 119 citations in OpenAlex.
- Extracellular Vesicles in Oral Squamous Cell Carcinoma and Oral Potentially Malignant Disorders: A Systematic Review.International journal of molecular sciences · 2020Pooled it
- Niches in cancer: from primary tumors to metastatic disease.Journal of hematology & oncology · 2026Review
- The CCT6A paradigm: biomarker potential and therapeutic challenges in oncology and beyond.Molecular biology reports · 2026Review
- Immune patterns of the tumor microenvironment in PD-L1Genes & diseases · 2026Article
- Ginseng-derived vesicle-like nanoparticles deliver pgi-MIR6136a-p3 for sepsis therapy via ELF3/NF-κB signaling axis.Journal of nanobiotechnology · 2026Article
- Multidimensional liquid biopsy in bladder cancer: advances in circulating tumor cells, circulating tumor DNA, exosomes, and metabolomics.The oncologist · 2026Review
- Emerging Salivary Exosome Nanodiagnostics for Early Oral Squamous Cell Carcinoma: Platforms, Biomarkers, and Future Perspectives.International journal of nanomedicine · 2026Review
- Knockdown of HGH1 in breast cancer cell lines can inhibit the viability, invasion and migration of tumor cells.Cell adhesion & migration · 2025Article
- Novel mutations of SRPX facilitate the stemness and malignant progression of glioma.British journal of cancer · 2025Article
- Mechanism of Centrosomal Protein 55 (CEP55) Loading Into Exosomes.Journal of extracellular vesicles · 2025Article
- CEP55 Promotes Acral Melanoma Progression via MAPK Pathway and Predicts Survival Following Immunotherapy.Oncology research · 2025Article
- Current state of cancer immunity cycle: new strategies and challenges of using precision hydrogels to treat breast cancer.Frontiers in immunology · 2025Review
- Saliva in Balancing Oral and Systemic Health, Oral Cancer, and Beyond: A Narrative Review.Cancers · 2024Review
- Serine related gene CCT6A promotes metastasis of hepatocellular carcinoma via interacting with RPS3.Functional & integrative genomics · 2024Article
- Unveiling potential: urinary exosomal mRNAs as non-invasive biomarkers for early prostate cancer diagnosis.BMC urology · 2024Article
- Microvesicles-delivering Smad7 have advantages over microvesicles in suppressing fibroblast differentiation in a model of Peyronie's disease.BMC biotechnology · 2024Article
- Emerging roles of exosomes in oral diseases progression.International journal of oral science · 2024Review
- Centrosomal Protein 55 (CEP55) Drives Immune Exclusion and Resistance to Immune Checkpoint Inhibitors in Colorectal Cancer.Vaccines · 2024Article
- Extracellular vesicles from cancer cell lines of different origins drive the phenotype of normal oral fibroblasts in a CAF-like direction.Frontiers in oncology · 2024Article
- Revolutionizing Brain Drug Delivery: Buccal Transferosomes on the Verge of a Breakthrough.Recent advances in drug delivery and formulation · 2024Review
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExosomes are extracellular vesicles released by almost all cell types, including cancer cells, into bodily fluids such as saliva, plasma, breast milk, semen, urine, cerebrospinal fluid, amniotic fluid, synovial fluid and sputum. Their key function being intercellular communication with both neighbouring as well as distant cells. Cancer exosomes have been shown to regulate organ-specific metastasis. However, little is known about the functional differences and molecular consequences of normal cells responding to exosomes derived from normal cells compared to those derived from cancer cells.
methodsHere, we characterised and compared the transcriptome profiles of primary human normal oral keratinocytes (HNOK) in response to exosomes isolated from either primary HNOK or head and neck squamous cell carcinoma (HNSCC) cell lines.
resultsIn recipient HNOK cells, we found that regardless of normal or cancer derived, exosomes altered molecular programmes involved in matrix modulation (MMP9), cytoskeletal remodelling (TUBB6, FEZ1, CCT6A), viral/dsRNA-induced interferon (OAS1, IFI6), anti-inflammatory (TSC22D3), deubiquitin (OTUD1), lipid metabolism and membrane trafficking (BBOX1, LRP11, RAB6A). Interestingly, cancer exosomes, but not normal exosomes, modulated expression of matrix remodelling (EFEMP1, DDK3, SPARC), cell cycle (EEF2K), membrane remodelling (LAMP2, SRPX), differentiation (SPRR2E), apoptosis (CTSC), transcription/translation (KLF6, PUS7). We have also identified CEP55 as a potential cancer exosomal marker.
conclusionsIn conclusion, both normal and cancer exosomes modulated unique gene expression pathways in normal recipient cells. Cancer cells may exploit exosomes to confer transcriptome reprogramming that leads to cancer-associated pathologies such as angiogenesis, immune evasion/modulation, cell fate alteration and metastasis. Molecular pathways and biomarkers identified in this study may be clinically exploitable for developing novel liquid-biopsy based diagnostics and immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.